What did Oppenheimer change in its NKTR analyst rating on March 13, 2026?

Oppenheimer maintained an **Outperform** rating and raised the price target to **$140** from **$115** on March 13, 2026, per StreetInsider and market reports.

How should investors interpret the NKTR analyst rating and new price target?

The NKTR analyst rating of Outperform signals expected outperformance versus peers. The **$140** target shows analyst upside, but investors should watch upcoming clinical and commercial catalysts.

Does the Oppenheimer note mean I should buy NKTR now?

Oppenheimer’s maintained Outperform and **$140** target show confidence, not a guarantee. Use the NKTR analyst rating as one input and review risks, position size, and catalyst timelines.

Where can I read the analyst note and market coverage on NKTR?

Oppenheimer’s update was published via StreetInsider and summarized on Investing.com. See Oppenheimer’s note on StreetInsider [source](https://www.streetinsider.com/Analyst+Comments/Nektar+Therapeutics+%28NKTR%29+PT+Raised+to+%24140+at+Oppenheimer/26158301.html) and a market summary on Investing.com

Analyst Ratings

Oppenheimer Maintains Outperform on Nektar Therapeutics (NKTR) March 2026

ByHuzaifa Zahoor March 14, 2026March 14, 2026

On March 13, 2026 Oppenheimer maintained an Outperform rating for Nektar Therapeutics and raised its price target to $140. The NKTR analyst rating change reflects Oppenheimer’s updated view after clinical updates and company commentary. Oppenheimer left the rating unchanged while increasing the price target from $115 to $140, signaling more upside potential. This note came with only a small intraday price move of 0.31% ($0.23) and follows heavy analyst focus on NKTR in recent months.